The phase 2 clinical trial result of JKB-121 for NASH has been presented at International Liver Congress™ 2018.

TaiwanJ Pharmaceuticals is pleased to announce that the phase 2 clinical trial result of its JKB-121 has been accepted by the European Association for the Study of the Liver (EASL) to be presented in the late breaker section of International Liver Congress™ 2018. The presentation of JKB-121 for NASH was selected for the “Best of ILC 2018” slide deck. The International Liver Congress™ 2018 will take place in Paris, France, April 11-15, 2018.
JKB-121, a toll-like receptor 4 (TLR4) antagonist with immunomodulating and hepatoprotectant property, just completed its 24-week Phase 2, randomized, multi-dose, double-blinded, and placebo-controlled clinical trial which aims to determine safety and efficacy in 65 non-alcoholic steatohepatitis (NASH) patients. JKB-121 (5 and 10 mg) was found to be well tolerated but do not demonstrate statistically significant improvement in fatty liver, liver enzymes, and metabolic biomarkers over placebo. Currently, TaiwanJ Pharmaceuticals is seeking collaboration partners to conduct further NASH trials for the JKB-121. The present results of JKB-121 will be used as the study design.